Hyperlipoproteinemia Type III (Disease Or Phenotype)

Omim:617347

Nci:C34710

Msh:D006952

Mondo:MONDO:18473

Medcin:MEDCIN:33853

Mdr:MDR:10064708

Id:6f389fc1-6092-54b0-bcb7-a6084d3ffec8

Icpc2icd10eng:MTHU029781

Efo:EFO:1645

Doid:DOID:3145

Chv:CHV:6422

Results found

Linked to

	Label	Description
	(E)-(3R,5S)-7-[4-(4-Fluoro-phenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-3,5-dihydroxy-hept-6-enoic acid anion indication Hyperlipoproteinemia Type III Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from IDG
	simvastatin indication Hyperlipoproteinemia Type III Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from IDG
	Pravastatin indication Hyperlipoproteinemia Type III Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from IDG
	atorvastatin indication Hyperlipoproteinemia Type III Knowledge Graph Assertion (Entity type)	A Knowledge Graph Assertion from IDG

(E)-(3R,5S)-7-[4-(4-Fluoro-phenyl)-6-isopropyl-2-(methanesulfonyl-methyl-amino)-pyrimidin-5-yl]-3,5-dihydroxy-hept-6-enoic acid anion indication Hyperlipoproteinemia Type III

Knowledge Graph Assertion (Entity type)

A Knowledge Graph Assertion from IDG

simvastatin indication Hyperlipoproteinemia Type III

Knowledge Graph Assertion (Entity type)

A Knowledge Graph Assertion from IDG

Pravastatin indication Hyperlipoproteinemia Type III

Knowledge Graph Assertion (Entity type)

A Knowledge Graph Assertion from IDG

atorvastatin indication Hyperlipoproteinemia Type III

Knowledge Graph Assertion (Entity type)

A Knowledge Graph Assertion from IDG

DISPLAY PER PAGE

CFDE Workbench

Consortium

Community

Resources

@CFDE Workbench 2025

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

Consortium

Community

Resources

CFDE Workbench

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2025